Overview
Cilnidipine is a dihydropyridine calcium antagonist. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995. Compared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium antagonists. This drug is approved in China, Japan, Korea, India, and several countries in the European Union.
Indication
Cilnidipine is indicated for the management of hypertension for end-organ protection. It is reported to be useful in elderly patients and in those with diabetes and albuminuria. Cilnidipine has been increasingly used in patients with chronic kidney disease Hypertension is the term used to describe the presence of high blood pressure. The blood pressure is generated by the force of the blood pumped from the heart against the blood vessels. Thus hypertension is caused when there is too much pressure on the blood vessels and this effect can damage the blood vessel.
Associated Conditions
- Hypertension
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2009/04/29 | Phase 2 | UNKNOWN | Ministry of Health, Labour and Welfare, Japan | ||
2006/05/15 | Phase 3 | Completed | |||
2006/05/15 | Phase 4 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Cilnidipine Capsules | 国药准字H20070110 | 化学药品 | 胶囊剂 | 12/22/2021 | |
| Cilnidipine Capsules | 国药准字H20080602 | 化学药品 | 胶囊剂 | 8/3/2023 | |
| Cilnidipine Capsules | 国药准字H20070109 | 化学药品 | 胶囊剂 | 12/22/2021 | |
| Cilnidipine Capsules | 国药准字H20080066 | 化学药品 | 胶囊剂 | 9/2/2022 | |
| Cilnidipine Soft Capsules | 国药准字H20080705 | 化学药品 | 软胶囊剂 | 8/1/2023 | |
| Cilnidipine Tablets | 国药准字H20020585 | 化学药品 | 片剂 | 7/28/2020 | |
| Cilnidipine Tablets | 国药准字H20080668 | 化学药品 | 片剂 | 9/13/2022 | |
| Cilnidipine Tablets | 国药准字H20040440 | 化学药品 | 片剂 | 4/7/2020 | |
| Cilnidipine Tablets | 国药准字H20020577 | 化学药品 | 片剂 | 4/7/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.